Skip to main content
Pangen Biotech Inc. logo

Pangen Biotech Inc. — Investor Relations & Filings

Ticker · 222110 ISIN · KR7222110009 KO Manufacturing
Open in API
Filings indexed 333 across all filing types
Latest filing 2024-03-13 Proxy Solicitation & In…
Country KR South Korea
Listing KO 222110

About Pangen Biotech Inc.

https://pangen.com/layout/eng/home.php

Pangen Biotech Inc. is a biotechnology company specializing in the research, development, and manufacturing of biopharmaceuticals. The company utilizes its proprietary platform technologies, particularly those based on Chinese Hamster Ovary (CHO) cell lines, for the production of complex protein therapeutics. Its primary business activities include the development of a pipeline of biosimilar products, such as Erythropoietin (EPO) and Aflibercept. In addition to its own product pipeline, Pangen Biotech offers Contract Development and Manufacturing Organization (CDMO) services, providing expertise in cell line development and biopharmaceutical production to other firms. The company also supplies reagents and kits for research applications.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Pangen Inc. It contains the meeting date, location, agenda items (financial statement approval, director appointments, etc.), and detailed management reference materials (사외이사 활동내역, 최대주주 거래내역, 사업의 개요). This is a standard proxy statement and meeting notice package provided to shareholders to solicit votes for the upcoming AGM.
2024-03-13 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Pangen. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and business purpose changes) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting details and agenda, which falls under the Proxy Solicitation & Information Statement category.
2024-03-12 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal announcement regarding the submission of an audit report ('감사보고서 제출') by the company Pangen. It provides key financial highlights, audit opinions, and financial data tables (assets, liabilities, equity, etc.) as required by regulatory disclosure standards. Since it is a summary announcement of the audit report submission rather than the full, multi-page audited financial statement document itself, it falls under the category of Audit Report / Information. FY 2023
2024-03-07 Korean
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory announcement regarding the adjustment of the conversion price of convertible bonds (CB). It details the change in conversion price, the number of convertible shares, the reason for the adjustment (market price fluctuation), and the calculation methodology. This type of filing relates to changes in capital structure and financial instruments, which falls under the 'Capital/Financing Update' category.
2024-02-20 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Pangen) regarding a 'Single Sales/Supply Contract' amendment. It details a change in the contract end date and provides specific financial terms of the supply agreement. Since this is a specific regulatory disclosure regarding a material contract update that does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2024-02-14 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Pangen) regarding a 'Single Sale/Supply Contract' amendment. It details a change in the contract end date for a pharmaceutical manufacturing agreement. Since this is a specific regulatory disclosure regarding a material contract update that does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2024-01-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.